Determination of Regulatory Review Period for Purposes of Patent Extension; ENHERTU

Summary

The Food and Drug Administration (FDA) has determined the regulatory review period for the patent extension of ENHERTU, a human biological product, following the submission of applications to the US Patent and Trademark Office (USPTO). This determination is being published as required by law.